Refractory idiopathic thrombocytopenic purpura treated with the soluble tumor necrosis factor receptor etanercept.
Litton
Gregory
G
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003078:Colchicine / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003622:Dapsone / Q000627:therapeutic use; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D064747:Lansoprazole; D008297:Male; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy* / Q000601:surgery; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D013156:Splenectomy; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D064747:Lansoprazole; D003622:Dapsone; D000068800:Etanercept; D003078:Colchicine